Table 3.

Clinical characteristics of patients.

	Gender	Age	Histology	Clinical Stage	Asbestos Exposure	Time between Biopsies (Months)	Treatment between Biopsies	OS (Months)
Patient 1	F	53	Epithelioid	II	Yes	7	None	25
Patient 2	F	54	Epithelioid	II	Yes	10	Cisplatin–pemetrexed Anetumab–ravtansine	21
Patient 3	M	71	Epithelioid	II	Yes	10	Cisplatin–pemetrexed Oncolytic virus	39
Patient 4	M	62	Epithelioid	III	Yes	10	Cisplatin–pemetrexed	23
Patient 5	M	60	Epithelioid	III	Yes	14	Cisplatin–pemetrexed Oncolytic virus	31
Patient 6	F	83	Epithelioid	III	Yes	8	None	17
Patient 7	M	84	Biphasic	III	Yes	1	None	19
Patient 8	M	62	Epithelioid	II	No	3	Cisplatin–pemetrexed	43
Patient 9	M	69	Epithelioid	III	Yes	33	Cisplatin–pemetrexed–bevacizumab, pembrolizumab	34
Patient 10	M	59	Epithelioid	III	Yes	16	Cisplatin–pemetrexed, vinorelbine	17

F: female, M: male.